Adjuvant proton beam therapy in patients with grade 2 meningiomas
Open Access
- 1 March 2024
- journal article
- research article
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 15, 62
Abstract
The World Health Organization (WHO) grade 2 meningiomas behave aggressively with a high proclivity toward recurrence despite maximal surgical resection. Our institution, a pioneer of proton therapy, uses exclusively proton beam radiation, and thus, we present a retrospective cohort analysis of patients with WHO grade 2 meningiomas treated with adjuvant proton beam therapy (PBT) at our institution between 2007 and 2019. The effects of adjuvant PBT were evaluated. Data collected include diagnosis, gender, histological subtype, WHO grade, the extent of surgical resection, adjuvant PBT radiation, details of the PBT radiation, recurrence, any additional PBT radiation, systemic medical therapy, and disease-specific survival. Among the WHO grade 2 meningiomas (n = 50) recommended PBT, 80% and 78% of patients with gross-total resection (GTR) and subtotal resection (STR), respectively, followed through with PBT. The median radiation dose of PBT was 59.5 Gy and 59.92 Gy for patients with GTR and STR, respectively, with a median of 33 fractions delivered in 1.8 Gy doses for both groups. Combined 3-year progression-free survival (PFS) was 96%, and 5-year PFS was 92%. Combined overall survival was 95% at five years. Minimal radiation side effects were reported with no grade 3 or higher toxicities. Our results suggest that adjuvant PBT is well tolerated with minimal radiation toxicity. Alternative to photon radiation, PBT may be considered at least as safe and effective for adjuvant treatment of WHO grade 2 meningiomas when it is available.Keywords
This publication has 19 references indexed in Scilit:
- A Systematic Review of Ion Radiotherapy in Maintaining Local Control Regarding Atypical and Anaplastic MeningiomasWorld Neurosurgery, 2019
- Bringing Europe together in building clinical evidence for proton therapy – the EPTN–ESTRO–EORTC endeavorActa Oncologica, 2019
- Clinical applications of proton and carbon ion therapySeminars in Oncology, 2019
- Adjuvant postoperative high-dose radiotherapy for atypical and malignant meningioma: A phase-II parallel non-randomized and observation study (EORTC 22042-26042)Radiotherapy and Oncology, 2018
- Long-Term Clinical Outcomes of Pencil Beam Scanning Proton Therapy for Benign and Non-benign Intracranial MeningiomasInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2017
- Volumetric response of intracranial meningioma after photon or particle irradiationActa Oncologica, 2016
- CyberKnife Stereotactic Radiosurgery for Atypical and Malignant MeningiomasWorld Neurosurgery, 2016
- Proton therapy for atypical meningiomasJournal of Neuro-Oncology, 2015
- Stereotactic radiosurgery of World Health Organization grade II and III intracranial meningiomasCancer, 2011
- Carbon ion radiation therapy for high-risk meningiomasRadiotherapy and Oncology, 2010